Stay updated on Tucatinib Plus Trastuzumab in HER2+ Colorectal Cancer Clinical Trial
Sign up to get notified when there's something new on the Tucatinib Plus Trastuzumab in HER2+ Colorectal Cancer Clinical Trial page.

Latest updates to the Tucatinib Plus Trastuzumab in HER2+ Colorectal Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov site footer version changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe site footer now identifies the website as revision v3.8.0 instead of v3.7.2. The study record content remains unchanged.SummaryDifference0.0%

- Check28 days agoChange DetectedA notice says NIH websites are transitioning terminology from “Artificial Intelligence” to “Super Intelligence” and directs visitors to transition updates and FAQs.SummaryDifference0.3%

- Check35 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.0%

- Check42 days agoChange DetectedThe ClinicalTrials.gov footer now identifies the site as revision v3.7.1 instead of v3.7.0.SummaryDifference0.0%

- Check63 days agoChange DetectedA new revision entry v3.7.0 was added to the history, replacing the previous v3.6.6 entry in the list.SummaryDifference0.0%

Stay in the know with updates to Tucatinib Plus Trastuzumab in HER2+ Colorectal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tucatinib Plus Trastuzumab in HER2+ Colorectal Cancer Clinical Trial page.